The Michigan Supreme Court has ruled in favor of Attorney General Dana Nessel in a closely divided 4-3 decision, reopening the path for a state price-gouging investigation involving a major insulin manufacturer. The decision reversed a lower court ruling that had blocked the case from moving forward.
Beyond the immediate dispute, the ruling also carries wider implications for consumer law in Michigan. According to the case description, the high court overruled earlier decisions that had narrowed the reach of the state’s consumer protection statute, a shift that could strengthen enforcement efforts in similar cases.
At the center of the dispute is whether Michigan can use its consumer protection law to examine pricing conduct tied to insulin, a medication that has drawn intense public scrutiny because of affordability concerns. By siding with Nessel, the court allowed the attorney general’s investigation to continue rather than ending it at the lower-court stage.
The decision marks an important win for the attorney general and signals a notable change in how Michigan’s consumer protection law may be applied going forward. While the full impact will depend on future cases, the ruling appears to give state officials broader room to pursue investigations involving alleged harm to consumers.
